JAM
IBB icon

JW Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

JW Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,484
Closed -$1.94M – 25
2017
Q3 		$1.94M Buy
+17,484
New +$1.87M 1.42% 17

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JW Asset Management's IBB Position: Q4 2017 in Review

JW Asset Management sold out of iShares Biotechnology ETF (IBB) in Q4 2017, closing a stake of 17,484 shares — an estimated $1.94M sold.

JW Asset Management first reported a position in IBB in Q3 2017 and held it in 1 quarter. The position peaked at $1.94M in Q3 2017. 624 funds tracked by Wall St. Rank hold IBB as of Q4 2017.

  • JW Asset Management reported no remaining iShares Biotechnology ETF position as of Q4 2017 after selling out during the quarter.
  • JW Asset Management sold 17,484 iShares Biotechnology ETF shares in Q4 2017, an estimated $1.94M.
  • JW Asset Management first reported a position in iShares Biotechnology ETF in Q3 2017 and held it in 1 quarter.
  • JW Asset Management's iShares Biotechnology ETF position peaked at $1.94M in Q3 2017.
  • 624 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2017.

Based on JW Asset Management's 13F filing for Q4 2017, filed 12 Feb 2018.